JP2019510078A - Ｉｌ−６アンタゴニスト製剤およびその使用 - Google Patents

Ｉｌ−６アンタゴニスト製剤およびその使用 Download PDF

Info

Publication number
JP2019510078A
JP2019510078A JP2018563405A JP2018563405A JP2019510078A JP 2019510078 A JP2019510078 A JP 2019510078A JP 2018563405 A JP2018563405 A JP 2018563405A JP 2018563405 A JP2018563405 A JP 2018563405A JP 2019510078 A JP2019510078 A JP 2019510078A
Authority
JP
Japan
Prior art keywords
antibody
formulation
seq
fragment
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018563405A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510078A5 (OSRAM
Inventor
グリゴリオス ザービス−パパストートシス，
グリゴリオス ザービス−パパストートシス，
パトリシア ロウデン，
パトリシア ロウデン，
Original Assignee
セセン バイオ， インコーポレイテッド
セセン バイオ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セセン バイオ， インコーポレイテッド, セセン バイオ， インコーポレイテッド filed Critical セセン バイオ， インコーポレイテッド
Publication of JP2019510078A publication Critical patent/JP2019510078A/ja
Publication of JP2019510078A5 publication Critical patent/JP2019510078A5/ja
Priority to JP2022058898A priority Critical patent/JP2022084922A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
JP2018563405A 2016-02-23 2017-02-23 Ｉｌ−６アンタゴニスト製剤およびその使用 Pending JP2019510078A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022058898A JP2022084922A (ja) 2016-02-23 2022-03-31 Ｉｌ－６アンタゴニスト製剤およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662298774P 2016-02-23 2016-02-23
US62/298,774 2016-02-23
PCT/US2017/019131 WO2017147293A1 (en) 2016-02-23 2017-02-23 Il-6 antagonist formulations and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022058898A Division JP2022084922A (ja) 2016-02-23 2022-03-31 Ｉｌ－６アンタゴニスト製剤およびその使用

Publications (2)

Publication Number Publication Date
JP2019510078A true JP2019510078A (ja) 2019-04-11
JP2019510078A5 JP2019510078A5 (OSRAM) 2020-03-26

Family

ID=59685584

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018563405A Pending JP2019510078A (ja) 2016-02-23 2017-02-23 Ｉｌ−６アンタゴニスト製剤およびその使用
JP2022058898A Pending JP2022084922A (ja) 2016-02-23 2022-03-31 Ｉｌ－６アンタゴニスト製剤およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022058898A Pending JP2022084922A (ja) 2016-02-23 2022-03-31 Ｉｌ－６アンタゴニスト製剤およびその使用

Country Status (11)

Country Link
US (2) US20190046642A1 (OSRAM)
EP (1) EP3419599A4 (OSRAM)
JP (2) JP2019510078A (OSRAM)
KR (1) KR20180116359A (OSRAM)
CN (1) CN108718522A (OSRAM)
AR (1) AR107708A1 (OSRAM)
AU (1) AU2017223687A1 (OSRAM)
BR (1) BR112018017031A2 (OSRAM)
CA (1) CA3012350A1 (OSRAM)
MX (1) MX2018010032A (OSRAM)
WO (1) WO2017147293A1 (OSRAM)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022531331A (ja) * 2019-05-01 2022-07-06 ノヴォ ノルディスク アー／エス 抗ｉｌ－６抗体製剤
JP2023042974A (ja) * 2021-09-15 2023-03-28 シスメックス株式会社 抗サイトカイン抗体の抗原に対する親和性を向上させる方法、抗サイトカイン抗体の製造方法及び抗サイトカイン抗体
JP2023514992A (ja) * 2020-02-21 2023-04-12 スピットファイア ファーマ エルエルシー Ｇｌｐ－１ｒおよびｇｃｇｒアゴニスト、製剤、ならびに使用方法
JP2023532046A (ja) * 2020-06-26 2023-07-26 トレフォイル セラピューティクス，インク． 組換え修飾線維芽細胞増殖因子およびそれを使用した治療

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3083971A1 (en) * 2017-11-30 2019-06-06 Bio-Thera Solutions, Ltd. Liquid formulation of humanized antibody for treating il-6 related diseases
CN120267817A (zh) * 2018-09-14 2025-07-08 田边三菱制药株式会社 含有人抗il-33单克隆抗体的医药用组合物
EP3873437A4 (en) * 2018-10-31 2022-08-03 Richter Gedeon Nyrt. AQUEOUS PHARMACEUTICAL FORMULATIONS
RU2745814C1 (ru) * 2020-06-05 2021-04-01 Закрытое Акционерное Общество "Биокад" Водная фармацевтическая композиция левилимаба и ее применение
WO2022026914A1 (en) * 2020-07-31 2022-02-03 Alamab Therapeutics, Inc. Anti-connexin antibody formulations
CN116261448A (zh) * 2020-08-19 2023-06-13 百奥泰生物制药股份有限公司 用于治疗il-6相关疾病的包含高浓度人源化抗体的液体制剂
KR20220028972A (ko) * 2020-08-31 2022-03-08 (주)셀트리온 안정한 약제학적 제제
US20230073821A1 (en) * 2021-08-27 2023-03-09 International Business Machines Corporation Antigen-binding proteins targeting coronavirus (cov) variants
CN114525235B (zh) * 2022-02-25 2023-07-14 郑州大学 一种提高人表皮生长因子分泌生产效率的方法
CN119923252A (zh) * 2022-09-30 2025-05-02 索尼特生物治疗公司 低剂量il-6制剂及其使用方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040191243A1 (en) * 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
JP2005508981A (ja) * 2001-11-08 2005-04-07 プロテイン デザイン ラブス インコーポレイティド Ｉｇｇ抗体の安定な液体医薬製剤
US20120121594A1 (en) * 2008-11-25 2012-05-17 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of arthritis
JP2015502959A (ja) * 2011-12-07 2015-01-29 アムジェン インコーポレイテッド ＩｇＧ２ジスルフィドアイソフォームの分離
JP2015519373A (ja) * 2012-06-01 2015-07-09 オプソテック コーポレイションＯｐｈｔｈｏｔｅｃｈ Ｃｏｒｐｏｒａｔｉｏｎ 抗ｐｄｇｆアプタマーおよびｖｅｇｆ拮抗薬を含む組成物
JP2015527402A (ja) * 2012-09-07 2015-09-17 コヒラス・バイオサイエンシズ・インコーポレイテッド 安定水性アダリムマブ製剤
JP2016503412A (ja) * 2012-11-08 2016-02-04 イレブン・バイオセラピユーテイクス・インコーポレイテツド Ｉｌ−６アンタゴニストおよびその使用本出願は、２０１２年１１月８日出願の米国特許出願第６１／７２３，９７２号および２０１３年６月６日出願の米国特許出願第６１／８３１，６９９号に対する優先権を請求する。先の出願の各々の全内容はこれにより、参照により本明細書中に組み込まれる。

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4548990A (en) 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ES2330052T3 (es) 1991-03-01 2009-12-03 Dyax Corporation Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas.
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
FR2734739B1 (fr) 1995-06-01 1997-07-11 Gec Alsthom Stein Ind Dispositif de surveillance d'un broyeur a boulets
EP0795743A3 (en) 1996-03-15 1998-02-25 Japan Tobacco Inc. Method and apparatus for infra-red moisture measurement
US5839430A (en) 1996-04-26 1998-11-24 Cama; Joseph Combination inhaler and peak flow rate meter
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6358058B1 (en) 1998-01-30 2002-03-19 1263152 Ontario Inc. Aerosol dispensing inhaler training device
ATE439592T1 (de) 1998-12-10 2009-08-15 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
ATE472609T1 (de) 2001-04-26 2010-07-15 Amgen Mountain View Inc Kombinatorische bibliotheken von monomerdomänen
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
JP2005532313A (ja) 2002-05-07 2005-10-27 コントロール・デリバリー・システムズ・インコーポレイテッド 薬物送達装置の形成方法
CA2506230A1 (en) 2002-11-15 2004-06-03 Centocor, Inc. Anti-angiogenic uses of il-6 antagonists
JP4503617B2 (ja) 2003-12-23 2010-07-14 ライナット ニューロサイエンス コーポレイション アゴニスト抗ｔｒｋＣ抗体および該抗体を用いる方法
PL1776384T3 (pl) 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
JP2008511337A (ja) 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
PL1966244T3 (pl) 2005-12-30 2012-08-31 Merck Patent Gmbh Przeciwciała anty-il-6 zapobiegające wiązaniu il-6 skompleksowanego z il-6ralpha do gp130
CA2644405A1 (en) 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
MX2008014692A (es) 2006-05-19 2009-08-18 Alder Biopharmaceuticals Inc Metodo de cultivo para obtener una poblacion clonal de celulas b especificas de antigeno.
CN101605532A (zh) 2007-02-16 2009-12-16 惠氏公司 含有山梨糖醇的蛋白质调配物
CN105001332B (zh) 2007-05-21 2018-12-04 奥尔德生物控股有限责任公司 针对il-6的抗体及其用途
CN101855336B (zh) * 2007-09-14 2019-07-30 赛诺菲巴斯德生物制剂有限责任公司 含艰难梭菌类毒素a和b的药物组合物
WO2009070243A2 (en) 2007-11-21 2009-06-04 Amgen Inc. Wise binding agents and epitopes
US20100187601A1 (en) 2007-12-12 2010-07-29 Fujio Masuoka Semiconductor device
WO2009090189A1 (en) 2008-01-15 2009-07-23 Abbott Gmbh & Co.Kg Powdered protein compositions and methods of making same
PT2328616E (pt) 2008-08-05 2015-08-26 Novartis Ag Composições e métodos para anticorpos dirigidos à proteína c5 do complemento
JP5033921B2 (ja) 2008-09-12 2012-09-26 株式会社ケーディエフ 噴水装置
US20120005773A1 (en) * 2008-10-01 2012-01-05 Aasen Eric D Transgenic plants with enhanced agronomic traits
MX2011005540A (es) 2008-11-26 2011-06-21 Glaxo Group Ltd Polipeptidos dominios variables de anticuerpos, y antagonistas.
CA2749200A1 (en) 2009-01-29 2010-08-05 Michael Bowen Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
PE20130643A1 (es) 2010-07-12 2013-06-07 Covx Technologies Ireland Ltd Conjugados de anticuerpos multifuncionales
UA120029C2 (uk) 2012-07-13 2019-09-25 Рош Глікарт Аг Спосіб зниження в'язкості біспецифічного антитіла до vegf/ang-2 та застосування такого антитіла для лікування судинних очних захворювань
KR20150070384A (ko) 2012-10-25 2015-06-24 메디뮨 엘엘씨 안정한 저점도 항체 제제
SG10201912985RA (en) * 2013-07-12 2020-02-27 Ophthotech Corp Methods for treating or preventing ophthalmological conditions
EP2898896A1 (en) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
DK4268843T3 (da) * 2014-11-07 2025-11-10 F Hoffmann La Roche Ltd Forbedrede IL-6-antistoffer
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508981A (ja) * 2001-11-08 2005-04-07 プロテイン デザイン ラブス インコーポレイティド Ｉｇｇ抗体の安定な液体医薬製剤
US20040191243A1 (en) * 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
US20120121594A1 (en) * 2008-11-25 2012-05-17 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of arthritis
JP2015502959A (ja) * 2011-12-07 2015-01-29 アムジェン インコーポレイテッド ＩｇＧ２ジスルフィドアイソフォームの分離
JP2015519373A (ja) * 2012-06-01 2015-07-09 オプソテック コーポレイションＯｐｈｔｈｏｔｅｃｈ Ｃｏｒｐｏｒａｔｉｏｎ 抗ｐｄｇｆアプタマーおよびｖｅｇｆ拮抗薬を含む組成物
JP2015527402A (ja) * 2012-09-07 2015-09-17 コヒラス・バイオサイエンシズ・インコーポレイテッド 安定水性アダリムマブ製剤
JP2016503412A (ja) * 2012-11-08 2016-02-04 イレブン・バイオセラピユーテイクス・インコーポレイテツド Ｉｌ−６アンタゴニストおよびその使用本出願は、２０１２年１１月８日出願の米国特許出願第６１／７２３，９７２号および２０１３年６月６日出願の米国特許出願第６１／８３１，６９９号に対する優先権を請求する。先の出願の各々の全内容はこれにより、参照により本明細書中に組み込まれる。

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022531331A (ja) * 2019-05-01 2022-07-06 ノヴォ ノルディスク アー／エス 抗ｉｌ－６抗体製剤
JP7701273B2 (ja) 2019-05-01 2025-07-01 ノヴォ ノルディスク アー／エス 抗ｉｌ－６抗体製剤
JP2025114623A (ja) * 2019-05-01 2025-08-05 ノヴォ ノルディスク アー／エス 抗ｉｌ－６抗体製剤
JP7755766B2 (ja) 2019-05-01 2025-10-16 ノヴォ ノルディスク アー／エス 抗ｉｌ－６抗体製剤
JP2025166156A (ja) * 2019-05-01 2025-11-05 ノヴォ ノルディスク アー／エス 抗ｉｌ－６抗体製剤
JP2023514992A (ja) * 2020-02-21 2023-04-12 スピットファイア ファーマ エルエルシー Ｇｌｐ－１ｒおよびｇｃｇｒアゴニスト、製剤、ならびに使用方法
JP7752619B2 (ja) 2020-02-21 2025-10-10 スピットファイア ファーマ エルエルシー Ｇｌｐ－１ｒおよびｇｃｇｒアゴニスト、製剤、ならびに使用方法
JP2023532046A (ja) * 2020-06-26 2023-07-26 トレフォイル セラピューティクス，インク． 組換え修飾線維芽細胞増殖因子およびそれを使用した治療
JP2023042974A (ja) * 2021-09-15 2023-03-28 シスメックス株式会社 抗サイトカイン抗体の抗原に対する親和性を向上させる方法、抗サイトカイン抗体の製造方法及び抗サイトカイン抗体

Also Published As

Publication number Publication date
US20220241414A1 (en) 2022-08-04
EP3419599A1 (en) 2019-01-02
CA3012350A1 (en) 2017-08-31
US20190046642A1 (en) 2019-02-14
KR20180116359A (ko) 2018-10-24
AU2017223687A1 (en) 2018-08-09
BR112018017031A2 (pt) 2019-01-22
JP2022084922A (ja) 2022-06-07
MX2018010032A (es) 2019-03-11
EP3419599A4 (en) 2019-09-11
US12048746B2 (en) 2024-07-30
CN108718522A (zh) 2018-10-30
WO2017147293A1 (en) 2017-08-31
AR107708A1 (es) 2018-05-23

Similar Documents

Publication Publication Date Title
US12048746B2 (en) IL-6 antagonist formulations and uses thereof
EP3024484B1 (en) Stabilized antibody compositions
JP6480338B2 (ja) Ｉｌ−６アンタゴニストおよびその使用
JP6594438B2 (ja) 改善されたｉｌ−６抗体
EP4649959A2 (en) Methods of treating an eye disorder
JP2013144715A (ja) 生物医薬品製剤のための緩衝剤
EP1758617A2 (en) Stable liquid and lyophilized formulation of proteins
US20240084043A1 (en) Methods of treating an eye disorder
KR102106914B1 (ko) Gm-csf를 중화하는 화합물을 포함하는 액체 제제
US20210379183A1 (en) METHODS OF TREATING IgA NEPHROPATHY WITH AN APRIL BINDING ANTIBODY
CN119255788A (zh) 降黏度赋形剂组合物和包含其的低黏度高浓缩蛋白质制剂
HK1261611A1 (en) Il-6 antagonist formulations and uses thereof
HK40027816A (en) Improved il-6 antibodies
HK40102410A (en) Improved il-6 antibodies
HK40075201B (zh) 稳定的水性抗-tfpi抗体制剂
HK1244008B (en) Improved il-6 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210726

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211130